Radiation Sensitization of HNSCC Cells by the dual PI3K / mTOR Inhibitor BEZ235 as a function of the Cell Cycle

被引：0
|
作者：
Brandt, F. W. [1 ]
Balzer, V [1 ]
Dreffke, K. [1 ]
Wittig, A. [1 ,2 ]
Dikomey, E. [1 ,3 ]
Arenz, A. [1 ]
Schoetz, U. [1 ]
Engenhart-Cabillic, R. [1 ]
机构：
[1] Philipps Univ Marburg, Klin Strahlentherapie & Radioonkol, Marburg, Germany
[2] Univ Klinikum Jena, Klin Strahlentherapie & Radioonkol, Jena, Germany
[3] UKE Hamburg, Lab Strahlenbiol & Expt Radioonkol, Hamburg, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2018年 / 194卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P19-3-jD
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [41] Effects of novel PI3K/mTOR inhibitors BKM120 and BEZ235 in comparison to everolimus in Head & Neck Squamous cell carcinomas (HNSCC).
    Hesbert, Aurelie
    Serova, Marie
    de Gramont, Armand
    Slimane, Khemaies
    Raymond, Eric
    Faivre, Sandrine
    CANCER RESEARCH, 2013, 73 (08)
  • [42] BEZ235, a dual PI3K/mTORC inhibitor, targets the DNA damage response leading to radiosensitization and senescence
    Azad, A.
    Natoli, A.
    Jackson, S.
    Maira, S. M.
    Hackl, W.
    Cullinane, C.
    McArthur, G. A.
    Solomon, B.
    EJC SUPPLEMENTS, 2010, 8 (07): : 35 - 35
  • [43] Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway
    Xiaolong Tang
    Amin Li
    Chunmei Xie
    Yinci Zhang
    Xueke Liu
    Yinghai Xie
    Binquan Wu
    Shuping Zhou
    Xudong Huang
    Yongfang Ma
    Weiya Cao
    Ruyue Xu
    Jing Shen
    Zhen Huo
    Shuyu Cai
    Yong Liang
    Dong Ma
    Nanoscale Research Letters, 16
  • [44] The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Kudoh, Akiko
    Nonaka, Michiko
    Kato, Misaki
    Nishimura, Mayumi
    Oumi, Nao
    Sato, Seiya
    Naniwa, Jun
    Sato, Shinya
    Shimada, Muneaki
    Kigawa, Junzo
    Harada, Tasuku
    ONCOLOGY REPORTS, 2014, 32 (02) : 553 - 558
  • [45] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    Bhende, P. M.
    Park, S. I.
    Lim, M. S.
    Dittmer, D. P.
    Damania, B.
    LEUKEMIA, 2010, 24 (10) : 1781 - 1784
  • [46] Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
    Masuda, Mitsuhiro
    Shimomura, Manami
    Kobayashi, Ken
    Kojima, Shuji
    Nakatsura, Tetsuya
    ONCOLOGY REPORTS, 2011, 26 (05) : 1273 - 1279
  • [47] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Roulin, Didier
    Waselle, Laurent
    Dormond-Meuwly, Anne
    Dufour, Marc
    Demartines, Nicolas
    Dormond, Olivier
    MOLECULAR CANCER, 2011, 10
  • [48] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    P M Bhende
    S I Park
    M S Lim
    D P Dittmer
    B Damania
    Leukemia, 2010, 24 : 1781 - 1784
  • [49] NVP-BEZ235, a dual PI3K/mTOR inhibitor, suppress tumorigenicity of ovarian clear cell carcinoma cells.
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Kudoh, Akiko
    Nonaka, Michiko
    Sato, Seiya
    Naniwa, Jun
    Sato, Shinya
    Shimada, Muneaki
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2012, 72
  • [50] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
12345